ALK and anaplastic large cell lymphoma: Clinical studies have supported ALK as an extremely attractive therapeutic target for NPM-ALK(+) ALCL, and several ALK inhibitors are actually at various stages of clinical development or have received FDA (US Food and Drug Administration) approval.